Figure 4
Figure 4. Irgm1−/− HSC function is rescued by the addition of homozygous disruption of Irgm3. (A) The absolute number of SPL cells per mouse is indicated. Data are representative of 2 experiments, each performed in triplicate. (B) Competitive BM were performed with the use of 2 × 106 WBM cells from CD45.2 WT, Irgm1−/−, Irgm3−/−, or Irgm1−/−Irgm3−/− donors admixed with 2 × 106 WBM competitor cells from CD45.1 WT mice. Data are representative of 2 independent experiments, each with 5-6 recipients per cohort. (C) LC3 aggregation was determined by immunohistochemistry in HSCs (CD150+ SPKLS) of WT, Irgm1−/−, Irgm3−/−, or Irgm1−/−Irgm3−/− mice. A minimum of 40 cells was assessed per genotype, and the percentage of cells with LC3 aggregation is shown in the bar graph. Data are representative of 2 independent experiments. The proportions are statistically different with 95% confidence according to a 2-sample test of proportions. ***P < .001.

Irgm1−/− HSC function is rescued by the addition of homozygous disruption of Irgm3. (A) The absolute number of SPL cells per mouse is indicated. Data are representative of 2 experiments, each performed in triplicate. (B) Competitive BM were performed with the use of 2 × 106 WBM cells from CD45.2 WT, Irgm1−/−, Irgm3−/−, or Irgm1−/−Irgm3−/− donors admixed with 2 × 106 WBM competitor cells from CD45.1 WT mice. Data are representative of 2 independent experiments, each with 5-6 recipients per cohort. (C) LC3 aggregation was determined by immunohistochemistry in HSCs (CD150+ SPKLS) of WT, Irgm1−/−, Irgm3−/−, or Irgm1−/−Irgm3−/− mice. A minimum of 40 cells was assessed per genotype, and the percentage of cells with LC3 aggregation is shown in the bar graph. Data are representative of 2 independent experiments. The proportions are statistically different with 95% confidence according to a 2-sample test of proportions. ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal